The U.S. Food and Drug Administration approved Sanofi’s new pediatric vaccine immunizing children against six diseases.
Roche said a late-stage clinical trial has shown the Swiss drugmaker’s influenza drug baloxavir marboxil significantly sped time to relief for patients highly vulnerable to serious complications.
Pfizer will pay German biotech firm BioNTech up to $425 million in an alliance to develop more effective influenza jabs, the latest major pharma company to bank on a promising new genetic approach.
Switzerland-based Roche announced a strong second quarterly report with a 7 percent increase in group sales for the first half of 2018 and a 20 percent increase in its core EPS.
Roche’s hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed the Swiss drugmaker’s new medicine reduced symptoms in people at high risk of complications.
The U.S. FDA accepted a New Drug Application and granted Priority Review for Genentech’s baloxavir marboxil as a single-dose, oral treatment for acute, uncomplicated influenza in people 12 years and older.
Statement from FDA Commissioner Scott Gottlieb, M.D. on the efficacy of the 2017-2018 influenza vaccine
Seasonal flu has been widespread in 2018, impacting millions of people across the country. It has been an especially challenging season, with high rates of hospitalization for both influenza and its complications, which include pneumonia and the exacerbation of chronic conditions such as asthma and congestive heart failure. Many schools have closed in an attempt to control the spread of the illness and doctor’s offices are packed with patients seeking diagnosis and antiviral treatment.
German biotech firm CureVac secured more financial backing for vaccine development projects from its investor the Bill & Melinda Gates Foundation, working on jabs to prevent malaria and influenza.
A private British company is developing a vaccine that would be the first in the world to fight all types of flu.